BioLineRx Ltd (BLRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioLineRx Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.108x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.11 Million) by net assets ($19.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioLineRx Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how BioLineRx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BioLineRx Ltd debt and liabilities for a breakdown of total debt and financial obligations.
BioLineRx Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioLineRx Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taoping Inc
NASDAQ:TAOP
|
-0.051x |
|
TRANSTEMA GROUP AB O.N.
F:9G8
|
-0.011x |
|
Miliboo SA
PA:ALMLB
|
-0.111x |
|
ISCC FINTECH SPA
F:L7H
|
N/A |
|
Metro Bank PLC
LSE:MTRO
|
0.026x |
|
Cherry AG
XETRA:C3RY
|
0.023x |
|
QPR Software Oyj
HE:QPR1V
|
-0.282x |
|
SARAMA RESOURCES LTD
F:48S1
|
N/A |
Annual Cash Flow Conversion Efficiency for BioLineRx Ltd (2008–2024)
The table below shows the annual cash flow conversion efficiency of BioLineRx Ltd from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see BLRX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.46 Million | $-43.87 Million | -3.259x | -90.63% |
| 2023-12-31 | $13.22 Million | $-22.61 Million | -1.710x | -231.27% |
| 2022-12-31 | $50.84 Million | $-26.24 Million | -0.516x | -49.07% |
| 2021-12-31 | $68.09 Million | $-23.57 Million | -0.346x | +67.13% |
| 2020-12-31 | $22.03 Million | $-23.21 Million | -1.053x | -55.13% |
| 2019-12-31 | $33.38 Million | $-22.67 Million | -0.679x | -15.98% |
| 2018-12-31 | $41.32 Million | $-24.19 Million | -0.585x | -50.68% |
| 2017-12-31 | $52.88 Million | $-20.55 Million | -0.389x | +6.22% |
| 2016-12-31 | $35.03 Million | $-14.51 Million | -0.414x | -39.23% |
| 2015-12-31 | $47.61 Million | $-14.17 Million | -0.298x | +34.72% |
| 2014-12-31 | $31.77 Million | $-14.48 Million | -0.456x | +73.68% |
| 2013-12-31 | $11.68 Million | $-20.23 Million | -1.732x | -28.90% |
| 2012-12-31 | $14.97 Million | $-20.11 Million | -1.344x | -169.77% |
| 2011-12-31 | $22.53 Million | $-11.22 Million | -0.498x | -261.89% |
| 2010-12-31 | $37.26 Million | $11.46 Million | 0.308x | +144.52% |
| 2009-12-31 | $31.13 Million | $-21.51 Million | -0.691x | +48.70% |
| 2008-12-31 | $20.75 Million | $-27.96 Million | -1.347x | -- |
About BioLineRx Ltd
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the t… Read more